SML3795
BAY-3827
≥98% (HPLC), AMPK (AMP-activated protein kinase) inhibitor, powder
别名:
AMPK inhibitor BAY3827, BAY 3827, N-[5-(3,5-Dicyano-1,2,6-trimethyl-1,4-dihydropyridin-4-yl)-6-fluoro-7-methyl-1H-indazol-3-yl]-2-ethylbenzamide, N-[5-(3,5-Dicyano-1,4-dihydro-1,2,6-trimethyl-4-pyridinyl)-6-fluoro-7-methyl-1H-indazol-3-yl]-2-ethylbenzamide
产品名称
BAY-3827, ≥98% (HPLC)
InChI key
OZFFKOSQNBBYCA-UHFFFAOYSA-N
SMILES string
N#CC1=C(N(C(C)=C(C#N)C1C2=CC3=C(NN=C3NC(C4=C(C=CC=C4)CC)=O)C(C)=C2F)C)C
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
BAY-3827 is a selective and potent inhibitor of AMPK (AMP-activated protein kinase) and RSK1 (ribosomal 6 kinase 1) that exhibit strong anti-proliferative activity in androgen-dependent prostate cancer cell lines. BAY-3827 strongly down-regulates lipase E (LIPE), cAMP-dependent protein kinase type II-beta regulatory subunit (PRKAR2B), serine-threonine kinase AKT3 and carnitine palmitoyl-transferase 1 (CPT1) family expression levels and impairs lipid flux.
Selective and potent inhibitor of AMPK and RSK1 that exhibit strong anti-proliferative activity in androgen-dependent prostate cancer cell lines
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models
Cellular oncology, 44(3), 581-594 (2021)
Rab8a as a mitochondrial receptor for lipid droplets in skeletal muscle
Developmental Cell, 58(4), 289-305 (2023)
Anti-Na+/K+-ATPase DR antibody attenuates UUO-induced renal fibrosis through inhibition of Na+/K+-ATPase ?1-dependent HMGB1 release
Zheng J, Lan P, Li M, Kang MC, Xun M, Ma X, Yan M, Sun D, Shen Y, Fu X, Ding X, Yan X, Xue WJ
International Immunopharmacology, 116, 109826-109826 (2023)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持